Hundreds of patients with cardiovascular diseases (both Israelis and tourists) were provided with relevant treatment in Hadassah while they were unable to get help in other clinics.
And this is not surprising: journalists often use the words "for the first time," "first," etc. when referring to the Institute of Cardiology of the Jerusalem Medical Center.
•In March 2019 Hadassah became the first and only clinic in Israel carrying out the correction of the mitral valve by third-generation MitraClip.
•In January 2018 Dr. David Luria from Hadassah Medical Center for the first time in Israel used a new technique of pacemaker implantation by the placing of an electrode into the bundle decreasing the number of possible complications.
•In November 2015 cardiologists from the Hadassah Medical Center Dr. David Luria and Dr. Yair Elitsur were the first in Israel to implant the innovative MICRA capsule - the smallest and most effective pacemaker in the world.
iMER (International Medical Evaluation and Referrals)
iMER is a Worldwide Health Services Provider and the exclusive representative of Hadassah University Hospital in Greece and Cyprus since March 2007.
This list could be continued with dozens of other examples: the State University Hospital Hadassah is constantly the first to develop and implement unique methods and technologies, often even faster than in the USA.
To know more about the unique methods of heart treatment in Hadassah and discounts or to arrange a consultation with one of the leading cardiologists contact us.
New catheterization system in Hadassah
In 2019 the new "Heart Center" in Hadassah presented next generation image-guided catheterization system Azurion. It allowed bringing cardiologic care in Israel to a new level due to higher safety and accuracy than before.
The system produces a high-quality image significantly increasing the level of diagnostics and reducing the procedure time. The level of radiation exposure during examination with Azurion is also decreased by 50-80% by reducing the amount of required contrast.
The system allows you:
• to execute a broad range of medical procedures,
• to collect precious diagnostic information,
• to minimize the possibility of the mistakes during the procedure,
• to significantly reduce the preparation time and procedure itself.
Azurion contains 52 advanced monitors, 8 cardiological ultrasound units designed for overweight people (PUREWAV technology), software for operational monitoring of heart functioning, and 40 telemetry sensors connected to the central system. Philips ultrasound machines use advanced xMATRIX 3D imaging technology.
Azurion consists of a set of innovative catheterization systems for performing various medical and diagnostic procedures (expansion of arteries, stent implantation, valve replacement and treatment of congenital malformations).
The third generation of MITRACLIP system is available only in Hadassah
Hadassah takes the leading place in the percutaneous mitral valve repair in Israel and Europe. In the past 3 years, the clinic has carried out a record number of such procedures - more than 100 successfully. More than 50 corrections were conducted by innovative technology MitraClip in 2018.
These performance indicators were the main reason for the world-famous American company ABBOTT to implement revolutionary technologies in the cardiological field in Hadassah in 2019. Hadassah became the first and the only clinic in Israel selected for its development. The third generation of MitraClip was the first of these new products.
When the mitral valve fails to close completely, blood leaks backward inside the heart — a condition called mitral regurgitation. This process can have many reasons: cardiomyopathy, myocardial infarction, coronary heart disease and many other factors leading to mitral valve insufficiency, i.e., tissue degeneration and valve weakness.
Regurgitation is a very dangerous phenomenon that causes high blood pressure, arrhythmia, heart failure, and stroke.
The open-heart mitral valve surgery had been the only treatment for this defect for a long time.
The latest less-invasive treatment MitraClip procedure eliminates the necessity for the surgery and allows more efficient and gentle repair as compared to the complete replacement of the valve with a prosthesis.
The MitraClip device is a small double-sided clip fabricated with metal alloys and polyester surface coverage. The MitraClip device grasps and keeps the mitral valve leaflets resulting in a fixed approximation of the mitral leaflets throughout the cardiac cycle.
The improved device arms are as much as 5 mm longer than the previous version. It would seem that simple change significantly reduced the procedure time, as it became more convenient for doctors to install MitraСlip device. It made it much more reliable as an enlarged MitraСlip device holds the valve parts much more efficiently. Besides the increased clip size, it also helps doctors to treat patients with mitral valve leaflets located at a greater distance than usual, making the correction procedure possible.
The MitraClip is delivered to the desired location using a thin catheter 8.1 mm thick which is inserted into the femoral artery through a small hole and brought to the heart under X-ray control. When folded the thickness of the clamp is only 5 mm and length is 15 mm.
As soon as cardiologists are sure that the end of the catheter is properly positioned the clip is pulled out and straightened. The clip is brought closer to the mitral valve leaflets in the opened position and with the help of a special device, it is forced to compress capturing the leaflets. Then the clamp is disconnected from the delivery system and the catheter is pulled out. As a result, the patient has only a small inconspicuous wound on the thigh.
The installation of a new device in the clinic is carried out by an experienced cardiologist, Dr. Menashe Shuvy, who was trained under the guidance of the best Canadian specialists.
The whole procedure takes from 1 to 3 hours. The patient can leave the hospital within 2-3 days.
The patient would experience significant improvement in terms of mitral regurgitation and quality of life soon after the procedure.
The patient will receive blood-thinning drugs and anticoagulants for some time after the procedure to reduce the risk of blood clots formation.
A Breakthrough Treatment of Aortic Aneurysms - NEXUS ™ Stent Graft System
At the end of June 2018, the leading Hadassah's cardiologist Dr. David Planer utilized NEXUS™ Stent Graft System recently developed by Endospan company, Herzliya, Israel.
Dr. Planer himself participated in the development and pre-clinical studies of this technology. Although the system is still in experimental treatment status and has not yet received FDA approval, 40 stenting procedures have already been successfully performed.
"I feel much better than all the previous years" - says Vera Nagovski, Dr. Planer’s 62-year-old patient who carried out the innovative procedure.
The aortic arch is a complex structure and its 3D copy is created in order to perform the successful procedure. By connecting it to a flow simulator the doctor can simulate future surgery.
"It's very unusual: to increase the precision of the surgical manipulations, doctors have to rehearse them on replicas," says Dr. Planer. Through cooperation with Israeli engineers and physicians, the stent-graft is delivered to a place in the aortic arch using a minimally invasive endovascular procedure. A doctor can replace the affected segment of the aorta and close the aneurysms using thin tubes. Dr. Planer worked as an expert during all of the NEXUS™ implantations together with Prof. Mario Lachat from the Center for Cardiovascular Diseases at the Zurich University.
To arrange an examination or treatment with leading Israeli cardiologists contact us.